TcL Pharma appoints board member and operations director

French biotech develops antibodies to treat auto-immune diseases

TcL Pharma, a French biotech company dedicated to the development of antibodies for the treatment of auto-immune diseases has appointed Didier Hoch to its board of directors and Jean-Hugues Masgnaux as operations director.

Hoch has 25 years’ experience in the pharmaceutical industry and in vaccines. Between 2000 and 2010 he ran Sanofi Pasteur MSD, where he led the launch of Gardasil. Prior to this, he carried out various management functions at Rhône Poulenc Rorer (1985-2000), then joined Aventis (Europe, Middle-East/African regions) from 2000 to 2010. He is also a past president (2003-2009) of the European Vaccines Manufacturers Association EVM, and since 2006 has presided over the French Pharmaceutical Companies Association LEEM.

Masgnaux began his career as a consultant at Innothera Laboratories & CNI, going on to become manager of Licences & Agreements at Servier Group and product manager for Fournier Group. Between 1996 and 2000 he progressed from senior product manager to regional sales director and then marketing manager at Bayer Pharma. Between 2000 and 2005 he was Infectiology marketing manager for the France subsidiary of the Gruenenthal group, then international project manager and marketing director. In 2005 he took on the role of president of Madaus Laboratories France, becoming president of the Rottapharm/Madaus Group. In July 2009, he set up M&M Conseil and among other activities works as a health expert for Capgemini Consulting.

You may also like

Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Subscribe now